Comparative Pharmacokinetics and Safety of Orally Disintegrating and Conventional Tablet Formulations of Zastaprazan in Healthy Subjects
Hyung‐Gun Kim, Seunghyun Kang, Sunyoung Min, Heejoo Hong, Moonjung Bae · 2026
Read Comparative Pharmacokinetics and Safety of Orally Disintegrating and Conventional Tablet Formulations of Zastaprazan in Healthy Subjects by Hyung‐Gun Kim, Seunghyun Kang, Sunyoung Min, Heejoo Hong, Moonjung Bae (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675658.txt.
Description
Hyung-Gun Kim and four co-authors test whether a melt-in-the-mouth version of an acid-blocking drug behaves the same as its ordinary tablet, in this 2026 study. The drug is zastaprazan, a potassium-competitive acid blocker for reflux and ulcer disease. The disintegrating tablet is meant to be easier to take, with or without water.
Fifty-four healthy volunteers each took, in rotating order, the standard tablet with water and the new tablet with and without water. Blood levels of the drug matched closely across all three ways of taking it, inside the accepted bioequivalence range. Peak timing and early exposure also lined up, with no extra surge in the first half hour from the quick-melting form. One volunteer reported two mild side effects and nothing serious occurred. The authors conclude the disintegrating tablet, taken either way, is pharmacokinetically equivalent to the standard tablet.
Catalog record
| CREATOR | Hyung‐Gun Kim, Seunghyun Kang, Sunyoung Min, Heejoo Hong, Moonjung Bae |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |